BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 7018057)

  • 1. Platelet preservation during cardiopulmonary bypass (CPB) with prostaglandin (PGE1) and prostacyclin (PGI2).
    van den Dungen JJ; Velders AJ; Karliczek GF; Homan van der Heide JN; Wildevuur CR
    Trans Am Soc Artif Intern Organs; 1980; 26():481-6. PubMed ID: 7018057
    [No Abstract]   [Full Text] [Related]  

  • 2. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
    Coppe D; Sobel M; Seamans L; Levine F; Salzman E
    J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental studies on platelet preservation with prostaglandin I2 and its derivative (OP-41483) during cardiopulmonary bypass].
    Takeda H
    Hokkaido Igaku Zasshi; 1989 Jul; 64(4):500-11. PubMed ID: 2511131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of platelets and their function in prolonged cardiopulmonary bypass using prostacyclin.
    Koshal A; Krausz MM; Utsunomiya T; Hechtman HB; Collins JJ; Cohn LH
    Circulation; 1981 Aug; 64(2 Pt 2):II44-8. PubMed ID: 7018736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some actions of prostacyclin (PGI2) on the cardiovascular system and the gastric microcirculation.
    Whittle BJ; Moncada S; Vane JR
    Acta Biol Med Ger; 1978; 37(5-6):725-8. PubMed ID: 369255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
    Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC; Ebert CD; Kim SW
    Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of platelet lysis, platelet consumption on oxygenator, and stabilization of platelet membrane with prostacyclin and ibuprofen during cardiopulmonary bypass surgery in dogs.
    Dewanjee MK; Vogel SR; Peterson KA; Lim MF; Kaye MP
    Trans Am Soc Artif Intern Organs; 1981; 27():197-202. PubMed ID: 7036497
    [No Abstract]   [Full Text] [Related]  

  • 11. Histologic and hemodynamic effects of prostacyclin and prostaglandin E1 following oleic acid infusion.
    Slotman GJ; Machiedo GW; Casey KF; Lyons MJ
    Surgery; 1982 Jul; 92(1):93-9. PubMed ID: 7046123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2 have anti-aggregating activity in chicken blood.
    Bult H; Wechsung E; Houvenaghel A; Herman AG
    Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):306-8. PubMed ID: 7013724
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
    Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic side effects of prostaglandin E1 in patients before and during cardiopulmonary bypass.
    Karliczek G; van den Dungen JJ; Brenken U; Eijsman L; Kootstra GJ; Homan van der Heide JN; Wildevuur CR
    Thorac Cardiovasc Surg; 1981 Feb; 29(1):55-9. PubMed ID: 6164120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass.
    van den Dungen JJ; Karliczek GF; Brenken U; van der Heide JN; Wildevuur CR
    Ann Thorac Surg; 1983 Apr; 35(4):406-14. PubMed ID: 6682305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the activities of prostacyclin and its stable analogs on the platelet aggregation and cardiovascular systems.
    Kawasaki A; Ishii K; Wakitani K; Tsuboshima M
    Adv Prostaglandin Thromboxane Res; 1980; 6():331-6. PubMed ID: 6992531
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation].
    Fabiani JN; Bunting S; Terrier E; O'Grady J; Fontaine B; Prigent C; Carpentier A; Vane J; Dubost C
    Arch Mal Coeur Vaiss; 1982 Mar; 75(3):241-8. PubMed ID: 6807240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The general pharmacology of prostacyclin PGI2, (PGX): a new prostaglandin especially active on the cardivascular system.
    Weeks JR
    Acta Biol Med Ger; 1978; 37(5-6):707-14. PubMed ID: 369253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary vasodilator activity of prostacyclin (PGI2) in the cat.
    Hyman AL; Kadowitz PJ
    Circ Res; 1979 Sep; 45(3):404-9. PubMed ID: 110490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.